News | Cardiogenic Shock | June 01, 2022

Recardio and FDA Reach Agreement on Pivotal Phase 3 Trial Design

Recardio Inc., a late stage clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the FDA concurs with Recardio's pivotal Heal-MI Phase 3 trial design with Dutogliptin in Acute Myocardial Infarction

Recardio Inc., a late stage clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the FDA concurs with Recardio's pivotal Heal-MI Phase 3 trial design with Dutogliptin in Acute Myocardial Infarction

Heart attack (myocardial infarction), illustration. A blocked coronary artery has led to heart muscle damage. Getty Images


June 1, 2022 — Recardio's Phase 2 trial results demonstrated the excellent safety profile of its lead drug Dutogliptin along with data suggesting potential positive effects on cardiac function and were presented in May at the World Congress on Acute Heart Failure 2022 in Madrid. Along with data suggesting potential positive effects on cardiac function, it was concluded that a pivotal study of this therapeutic approach in a large, adequately powered NDA-enabling study is warranted. 

After reviewing the Phase 2 trial results, the FDA agreed with the proposed trial design and sample size for the pivotal Phase 3 trial of Dutogliptin in co-adminstration with filgrastim in early recovery post-myocardial infarction. A comparable agreement was also reached with the EMA.

The global pivotal trial, named HEAL-MI, will enroll 4,000 acute myocardial infarction patients with STEMI but not specified left ventricular ejection fraction (LVEF) and with facilitated screening procedures, which will accelerate the total enrollment. The primary endpoint is a combined clinical endpoint with a Quality-of-Life evaluation as a secondary endpoint.  

Based on this advice, preparations are already under way for the trial that is intended to start in the course of 2022 and will enroll patients in the key global regions - US, Europe and China.

Dr. Roman Schenk, Recardio President commented: "We appreciate the positive agency feedback and are looking forward to contributing with this HEAL-MI pivotal trial to further therapeutic options for the respective patients with myocardial infarction."

For more information: www.recardio.eu

Related Content

Feature | Cardiogenic Shock

The global cardiogenic shock market was valued at US$ 3.29 Bn in 2021, and is expected to reach US$ 6.32 Bn by 2032 ...

Home May 12, 2022
Home
News | Cardiogenic Shock

March 22, 2022 – Women are less likely to receive lifesaving treatment for cardiogenic shock than men, according to ...

Home March 22, 2022
Home
Videos | Cardiogenic Shock

Srihari Naidu, M.D., FACC, FAHA, FSCAI, is the director of both the cardiac cath labs and Hypertrophic Cardiomyopathy ...

Home November 16, 2021
Home
Feature | Cardiogenic Shock | By Dave Fornell, Editor

April 29, 2021 — The results of a large, national heart attack study show that patients with cardiogenic shock survived ...

Home April 29, 2021
Home
Videos | Cardiogenic Shock

William O’Neill, M.D., medical director of the Center for Structural Heart Disease at Henry Ford Hospital, Detroit ...

Home April 28, 2021
Home
News | Cardiogenic Shock

August 3, 2020 — A three-year, investigator-led, prospective study of Japanese patients who received an Impella heart ...

Home August 03, 2020
Home
Videos | Cardiogenic Shock

Navin Kapur, M.D., FAHA, FACC, FSCAI, director, Acute Mechanical Circulatory Support Program and executive director of ...

Home July 15, 2020
Home
Videos | Cardiogenic Shock

William O’Neill, M.D., medical director of the Center for Structural Heart Disease at Henry Ford Hospital, Detroit ...

Home October 08, 2019
Home
News | Cardiogenic Shock

May 20, 2019 – A newly released expert consensus statement proposes a classification schema for cardiogenic shock (CS) ...

Home May 20, 2019
Home
News | Cardiogenic Shock

September 10, 2012 — Maquet Cardiovascular LLC announced 30-day results from the large, randomized, multicenter intra ...

Home September 10, 2012
Home
Subscribe Now